Former Employee of the Year at Eli Lilly and Company Accepts Chief Regulatory Officer Position at EDot.com/Nanoviricides, Inc.
|Dr. Krishna Menon, VMD, MRCS, PhD., Co-Inventor of Two "Blockbuster Drugs" Having Nearly a Billion Dollars in Annual Sales|
“I'm very excited at the prospect of joining Nanoviricides”
EDot.com, Inc. (Nanoviricides) (Pink Sheets:ECMM), announced that Dr. Krishna Menon accepted the position of Chief Regulatory officer. Dr. Menon is a former "Employee of the Year" and "President's Award" winner at Eli Lilly, having led several blockbuster drug projects there.
"I'm very excited at the prospect of joining Nanoviricides," Dr. Menon noted. "This technology represents, in my opinion, a market leading concept. It allows for a textbook finish for so many well conceived APIs, allowing delivery to target cells with lowest dosage, which increases efficacy and reduces toxicity." Dr. Menon further noted, "This concept was completely unimaginable just a short while ago. Many of the leading pharmaceutical companies now know how important this nano technology is, but still are uncertain how to develop it. A successful development of our patent pending materials will allow many well-conceived Active Pharmaceutical Ingredients (API's), presently failing in clinical trials to be reformulated. This will enable us to facilitate delivery of the API to the target cells utilizing the lowest possible dosages. This will create world class medications with markedly increased efficacy and markedly reduced toxicity."
Dr. Menon is returning from a trip to Singapore, where he was a distinguished speaker at the Drug Discovery & Development Asia Pacific conference http://www.drugdisc.com/3110.
The Company plans to begin its animal trials during the third quarter 2005, on the first of its targeted anti-viral nanoviricides(TM). Dr. Krishna Menon, Chief Regulatory Officer, will be supervising and monitoring the animal studies.
Dr. Menon is a well known Pharmaceutical Scientist and Executive. He was awarded the Employee of the Year, President's Award (1999) at Eli Lilly, where he was a co-inventor of two drugs, GEMZAR(R) and ALIMTA(R), which account for nearly one billion dollars in annual sales. Prior to that, he was Senior Research Scientist at Bayer. At present, he is on the board of directors of KARD Scientific, MA, and Biological Supplies, NY, and scientific advisor to Nexus Pharmaceuticals.
He is the holder of 7 US patents. Dr. Menon received a PhD from Harvard. While at Harvard, he performed pre-clinical studies on AZT, an important anti-HIV drug.
Nanoviricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. Nanoviricides, Inc. has exclusive license in perpetuity for technologies developed by Theracour Pharma for the five virus types HIV, HCV, Herpes, Asian (bird) flu and Influenza. A nanoviricide(TM) is a nanoparticle that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus. When a nanoviricide(TM) drug particle enters the patient's blood stream, it attacks and immobilizes circulating virus particles. Once this is done, the active pharmaceutical ingredient is injected into the virus by the nanoviricide(TM) particle, destroying it. The company plans to develop novel nanoviricide(TM) drugs first against HIV, and anticipates that in 2006/2007, it will license a product or products to major pharmaceutical companies.
Certain statements in this release, and other written or oral statements made by the Company, including the use of the words "expect," "anticipate," "estimate," "project," "forecast," "outlook," "target," "objective," "plan," "goal," "pursue," "on track," and similar expressions, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied. The Company assumes no obligation and does not intend to update these forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: competitive and general economic conditions, adverse effects of litigation, the timely development and acceptance of services, significant changes in the competitive environment, the failure to generate or the loss of significant numbers of customers, the loss of senior management, increased government regulation or the company's failure to integrate its acquired companies to achieve the synergies and efficiencies described in the "Management's Discussion and Analysis" section of the Company's filings with the Securities and Exchange Commission where applicable, which may be revised or supplemented in subsequent reports on SEC Forms 10-QSB and 8-K.